Skip to Content
Merck
CN
All Photos(1)

Documents

Safety Information

19-4497

Sigma-Aldrich

Metronidazole

SAJ first grade, ≥99.0%

Sign Into View Organizational & Contract Pricing
All Photos(1)
Synonym(s):
2-Methyl-5-nitroimidazole-1-ethanol
Empirical Formula (Hill Notation):
C6H9N3O3
CAS Number:
443-48-1
Molecular Weight:
171.15
Beilstein:
611683
EC Number:
207-136-1
MDL number:
MFCD00009750
UNSPSC Code:
12352005
PubChem Substance ID:
329751879

grade

SAJ first grade

Assay

≥99.0%

form

solid

availability

available only in Japan

mp

159-161 °C (lit.)

antibiotic activity spectrum

Gram-negative bacteria
parasites

Mode of action

DNA synthesis | interferes

SMILES string

CC1=NC=C([N+]([O-])=O)N1CCO

InChI

1S/C6H9N3O3/c1-5-7-4-6(9(11)12)8(5)2-3-10/h4,10H,2-3H2,1H3

InChI key

VAOCPAMSLUNLGC-UHFFFAOYSA-N

Looking for similar products? Visit Product Comparison Guide

General description

Chemical structure: imidazole

Pictograms

Health hazard
GHS08

Signal Word

Danger

Hazard Statements

H340,H350,H373

Hazard Classifications

Carc. 1B - Muta. 1B - STOT RE 2

WGK

WGK 3

Flash Point(F)

Not applicable

Flash Point(C)

Not applicable

Personal Protective Equipment

dust mask type N95 (US), Eyeshields, Gloves

Regulatory Information

新产品

Certificates of Analysis (COA)

Search for Certificates of Analysis (COA) by entering the products Lot/Batch Number. Lot and Batch Numbers can be found on a product’s label following the words ‘Lot’ or ‘Batch’.

Already Own This Product?

Find documentation for the products that you have recently purchased in the Document Library.

Visit the Document Library

Jayaram Lakshmaiah Narayana et al.
Oncotarget, 6(15), 12936-12954 (2015-05-24)
Helicobacter pylori infection is marked by a strong association with various gastric diseases, including gastritis, ulcers, and gastric cancer. Antibiotic treatment regimens have low success rates due to the rapid occurrence of resistant H. pylori strains, necessitating the development of
Konstantinos Z Vardakas et al.
International journal of antimicrobial agents, 40(1), 1-8 (2012-03-09)
The objective of this review was to evaluate the frequency of treatment failure and recurrence of Clostridium difficile infection (CDI) following treatment with vancomycin or metronidazole in recently performed studies (last 10 years). Searches in PubMed and Scopus were performed
Sonja Löfmark et al.
Clinical infectious diseases : an official publication of the Infectious Diseases Society of America, 50 Suppl 1, S16-S23 (2010-01-14)
Metronidazole has been used for the treatment of infections for >45 years and is still successfully used for the treatment of trichomoniasis, amoebiasis, and giardiasis. Anaerobic bacterial infections caused by Bacteroides species, fusobacteria, and clostridia respond favorably to metronidazole therapy.
Christina M Surawicz et al.
The American journal of gastroenterology, 108(4), 478-498 (2013-02-27)
Clostridium difficile infection (CDI) is a leading cause of hospital-associated gastrointestinal illness and places a high burden on our health-care system. Patients with CDI typically have extended lengths-of-stay in hospitals, and CDI is a frequent cause of large hospital outbreaks
T H I Brummer et al.
BJOG : an international journal of obstetrics and gynaecology, 120(10), 1269-1276 (2013-06-22)
To evaluate cefuroxime and metronidazole antibiotic prophylaxis. Observational nonrandomised 1-year prospective cohort study. Fifty-three hospitals in Finland. A total of 5279 women undergoing hysterectomy for benign indications, with cefuroxime given to 4301 and metronidazole given to 2855. Excluding other antibiotics
View All Related Papers

Our team of scientists has experience in all areas of research including Life Science, Material Science, Chemical Synthesis, Chromatography, Analytical and many others.

Contact Technical Service